Parnell Pharmaceuticals Holdings Ltd
Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproduc… Read more
Parnell Pharmaceuticals Holdings Ltd (PARNF) - Total Assets
Latest total assets as of September 2019: $0.00 USD
Based on the latest financial reports, Parnell Pharmaceuticals Holdings Ltd (PARNF) holds total assets worth $0.00 USD as of September 2019.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Parnell Pharmaceuticals Holdings Ltd - Total Assets Trend (2011–2021)
This chart illustrates how Parnell Pharmaceuticals Holdings Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Parnell Pharmaceuticals Holdings Ltd - Asset Composition Analysis
Current Asset Composition (December 2021)
Parnell Pharmaceuticals Holdings Ltd's total assets of $0.00 consist of 29.1% current assets and 70.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.2% |
| Accounts Receivable | $2.21 Million | 5.5% |
| Inventory | $3.74 Million | 9.3% |
| Property, Plant & Equipment | $13.38 Million | 33.4% |
| Intangible Assets | $15.04 Million | 37.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2021)
This chart illustrates how Parnell Pharmaceuticals Holdings Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Parnell Pharmaceuticals Holdings Ltd's current assets represent 29.1% of total assets in 2021, an increase from 16.5% in 2011.
- Cash Position: Cash and equivalents constituted 11.2% of total assets in 2021, up from 0.3% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 37.0% of total assets, an increase from 31.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 37.5% of total assets.
Parnell Pharmaceuticals Holdings Ltd Competitors by Total Assets
Key competitors of Parnell Pharmaceuticals Holdings Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Parnell Pharmaceuticals Holdings Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Parnell Pharmaceuticals Holdings Ltd generates 0.85x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Parnell Pharmaceuticals Holdings Ltd is currently not profitable relative to its asset base.
Parnell Pharmaceuticals Holdings Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.41 | 1.52 | 0.35 |
| Quick Ratio | 1.08 | 1.06 | 0.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.29 Million | $ 3.04 Million | $ -13.82 Million |
Parnell Pharmaceuticals Holdings Ltd - Advanced Valuation Insights
This section examines the relationship between Parnell Pharmaceuticals Holdings Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -1.2% |
| Total Assets | $40.11 Million |
| Market Capitalization | $742.72 USD |
Valuation Analysis
Below Book Valuation: The market values Parnell Pharmaceuticals Holdings Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Parnell Pharmaceuticals Holdings Ltd's assets decreased by 1.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Parnell Pharmaceuticals Holdings Ltd (2011–2021)
The table below shows the annual total assets of Parnell Pharmaceuticals Holdings Ltd from 2011 to 2021.
| Year | Total Assets | Change |
|---|---|---|
| 2021-12-31 | $40.11 Million | -1.16% |
| 2020-12-31 | $40.58 Million | +3.95% |
| 2019-12-31 | $39.04 Million | +16.58% |
| 2018-12-31 | $33.48 Million | +10.86% |
| 2017-12-31 | $30.20 Million | -36.52% |
| 2016-12-31 | $47.58 Million | +2.96% |
| 2015-12-31 | $46.21 Million | +17.25% |
| 2014-12-31 | $39.41 Million | +24.87% |
| 2013-12-31 | $31.56 Million | 0.00% |
| 2012-12-31 | $31.56 Million | +18.30% |
| 2011-12-31 | $26.68 Million | -- |